Renuology Announces a Practitioner First Approach to the Next Generation of Personalized Wellness

Renuology, co-founded by Ashlee Kaufman PA-C, MMS, is developing practitioner focused resources to support more individualized approaches to peptide and longevity care.

United States, October 19, 2026 -- The wellness industry is seeing growing interest in personalized health, genetic testing, and peptide-related care. As people explore options beyond traditional one-size-fits-all programs, healthcare practitioners face the challenge of evaluating emerging information, therapies, and clinical workflows.

Renuology, a precision wellness company led by CEO and Co-Founder Ashlee Kaufman, PA-C, MMS, aims to address this challenge through DNA insights, evidence-based peptides, clinical research, and practitioner education. Its initiatives include the Peptide DNA testing platform and PeptideRx.Health, a resource ecosystem supporting practices offering peptide-related wellness services.

Renuology’s approach centers on a simple principle: understanding the individual should come before recommending a product or protocol.

“I believe the biggest evolution in wellness isn't another product. It's understanding the person before choosing the product,” Kaufman said.

Moving Beyond One-Size-Fits-All Wellness

Traditional wellness programs often organize recommendations around broad goals such as energy, performance, nutrition, or longevity. While these categories provide a starting point, individuals differ in biology, medical history, lifestyle, and responses to interventions.

Renuology is developing a model that places greater emphasis on these differences. The company combines testing and scientific information with practitioner assessment rather than treating standard protocols as universal solutions.

DNA testing is one component of this approach. Genetic information can provide insight into inherited variations, but it does not independently establish a diagnosis or determine appropriate treatment. Interpretation requires clinical context, including medical history and other relevant assessments.

Renuology’s objective is to incorporate individual information into a broader, practitioner-led process, supporting wellness decisions that reflect the individual rather than generalized recommendations.

Building a Practitioner-Focused Peptide Model

A central part of Renuology’s business model is its practitioner-focused approach to peptide-related wellness. The company states that it does not simply sell peptides directly to consumers or encourage individuals to select protocols without professional guidance. Instead, Renuology works with practitioners and emphasizes clinical oversight, education, and product quality. The company describes its sourcing approach as focused on established pharmaceutical and compounding channels rather than gray-market sources.

It also states that its products undergo rigorous testing to support quality and consistency. Peptides are short chains of amino acids that can act as signaling molecules in the body. Their potential applications vary, and their safety, effectiveness, and regulatory status depend on the specific substance, formulation, and intended use. Professional oversight supports informed decision-making but does not establish FDA approval or individual suitability.

Peptide DNA Testing Adds Another Layer of Information

One of Renuology’s initiatives is its Peptide DNA testing platform, designed to provide healthcare practitioners with genetic insights that may support individualized wellness discussions.

The company is also expanding its DNA testing interests into areas including methylation, metabolic health, nutrition, performance, hormones, brain health, and overall wellness. These areas reflect Renuology’s broader interest in understanding individuals across multiple dimensions.

However, genetic information is not a substitute for medical history, physical examination, laboratory testing, or other clinical assessments. A genetic result may identify a variation associated with a biological process, but its implications can differ between individuals. Qualified professionals should interpret such information within the broader clinical context.

Renuology positions DNA insights as an additional resource within practitioner-led care rather than a standalone answer to health questions.

PeptideRx.Health Supports Clinical Education and Organization

Alongside its testing initiatives, Renuology developed PeptideRx.Health, a platform intended to support practices working with peptide related wellness services.

The platform brings together dosing tools, protocol organization, scientific information, education, and training. These resources are intended to help practitioners address practical challenges when developing or managing wellness programs.

Organized resources are increasingly relevant in a field where research, product information, and clinical practices continue to evolve. Practitioners may need to review multiple sources while maintaining documentation and considering patient-specific factors.

A digital platform can provide an organizational framework, but it does not replace clinical judgment, prescribing requirements, patient assessment, or applicable regulations.

Renuology’s broader infrastructure strategy reflects its view that responsible growth in peptide medicine requires practitioner education, quality controls, and clear boundaries around product and information use.

Ashlee Kaufman Brings Nearly Three Decades of Experience

Ashlee Kaufman’s professional background has shaped Renuology’s focus on science, product development, and individualized care. With more than 28 years of experience in health and wellness, product development, entrepreneurship, and business leadership, Kaufman has held leadership roles in the wellness industry, developed more than 150 nutritional products, and secured four product patents.

She also co-founded and successfully exited an e-commerce company during the early dot-com era, gaining experience in product formulation, operations, entrepreneurship, and business development.

Kaufman’s motivation for Renuology is also rooted in personal family experience. After losing her brother to Type 1 diabetes, she developed a deeper interest in helping people understand their health and access emerging treatment and technology options. “For decades, wellness has asked people to fit into protocols. I believe the next generation of wellness will build protocols around the person,” Kaufman said.

A Broader Vision for Precision Wellness

Renuology’s work reflects the evolving conversation around personalized wellness as testing, clinical research, and practitioner education continue to advance.

The company’s initiatives in DNA insights, peptide education, and clinical infrastructure are designed to support practitioners as they navigate this changing landscape. Rather than focusing on a single product category, Renuology is developing resources intended to help practices approach individualized wellness more systematically.

Kaufman describes this as part of a broader ambition for the company.

“I don't want Renuology to be known as another peptide or supplement company. I want us to be known as a company that helped change the conversation from ‘What should I take?’ to ‘What does my body actually need?’” Kaufman said.

Through testing initiatives, practitioner education, and its PeptideRx.Health platform, Renuology aims to contribute to a model of personalized wellness that combines individual information with qualified professional decision-making.

Renuology Recognized For Peptide Innovation

Renuology has also received recognition from Evergreen Awards, which named the company the Best Peptide Innovation Company in Juno Beach, Florida of 2026. The recognition highlights Renuology’s focus on personalization, practitioner education, genetic insights, peptide science, testing, and a practitioner-first approach to wellness. Led by CEO and Co-Founder Ashlee Kaufman, PA-C, MMS, Renuology was recognized for bringing structure and individualized thinking to the evolving peptide and longevity landscape. The award reflects the company’s precision wellness approach and does not independently assess the clinical effectiveness or safety of peptides, products, or protocols.

About Renuology

Renuology is a precision wellness company advancing a personalized approach to health, performance, and longevity. Founded by a practitioner, for practitioners, Renuology was built from firsthand experience with the need for better science, resources, and personalization in modern wellness.

By integrating genetic insights, peptide science, clinical research, and practitioner education, Renuology connects emerging science with individualized care. Its ecosystem includes advanced DNA testing, peptide education, strategic product and pharmacy partnerships, and PeptideRx.Health, a technology platform supporting peptide-focused practices.

At our core, we believe better wellness decisions begin with better information, empowering practitioners to create informed, personalized strategies for their patients

Ashlee Kaufman, PA-C, MMS - CEO and Co-Founder

More information is available at Renuology.com. To onboard go to Welcome.Renuology.com Business inquiries may be directed to [email protected]. Additional information is available through the company’s Instagram, Facebook, and LinkedIn profiles.

Contact Info:
Name: Ashlee Kaufman PA-C, MMS
Email: Send Email
Organization: Renuology
Website: https://renuology.com

Release ID: 89206545

If you come across any problems, discrepancies, or concerns related to the content contained within this press release that necessitate action or if a press release requires takedown, we strongly encourage you to reach out without delay by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will be readily accessible round-the-clock to address your concerns within 8 hours and take appropriate actions to rectify identified issues or support with press release removals. Ensuring accurate and reliable information remains our unwavering commitment.